CBeV (cyclophosphamide, bendamustine and etoposide) pre-autotransplant conditioning in persons with lymphoma

Bone Marrow Transplant. 2020 Jan;55(1):265-267. doi: 10.1038/s41409-019-0528-y. Epub 2019 Apr 23.

Authors

Affiliations

¹ Favaloro University Hospital, Buenos Aires, Argentina. gregjaim@gmail.com.
² Anchorena Hospital, Buenos Aires, Argentina. gregjaim@gmail.com.
³ Clinicas University Hospital Jose de San Martin, Buenos Aires, Argentina.
⁴ Anchorena Hospital, Buenos Aires, Argentina.
⁵ CEMIC, Buenos Aires, Argentina.
⁶ Alexander Fleming Institute, Buenos Aires, Argentina.
⁷ Favaloro University Hospital, Buenos Aires, Argentina.
⁸ Haematology Research Centre, Imperial College London, London, UK.

PMID: 31015577
DOI: 10.1038/s41409-019-0528-y

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Autografts
Bendamustine Hydrochloride
Cyclophosphamide
Etoposide
Hematopoietic Stem Cell Transplantation*
Humans
Lymphoma* / drug therapy
Transplantation Conditioning
Transplantation, Autologous

Substances

Etoposide
Cyclophosphamide
Bendamustine Hydrochloride